Glaxo Smith Kline results, Fiscal year 2022
Net profit, assets, equity and cash flow for Fiscal year 2022, against the same period a year earlier, from the published financial statements.
Net profit-185 millionEGP · −219.9% vs the same period a year earlier
Total assets3.19 billionEGP · +31.4% vs the same period a year earlier
Shareholders' equity1.73 billionEGP · +27.3% vs the same period a year earlier
Operating cash flow-335 millionEGP · −274.2% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Fiscal year 2022 was about -185 million EGP, down −219.9% from 155 million EGP in Fiscal year 2021.
- Total assets at the end of Fiscal year 2022 were about 3.19 billion EGP, and shareholders' equity about 1.73 billion EGP.
- Operating cash flow for Fiscal year 2022 was negative at 335 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2021Change
Net profit-185 million155 million−219.9%
Gross profit606 million759 million−20.2%
Total assets3.19 billion2.42 billion+31.4%
Total liabilities1.46 billion1.07 billion+36.5%
Shareholders' equity1.73 billion1.36 billion+27.3%
Total liabilities and equity3.19 billion2.42 billion+31.4%
Operating cash flow-335 million192 million−274.2%
Investing cash flow-242 million-35.15 million−587.8%
Financing cash flow-164 million-63.23 million−159.0%
Net change in cash-740 million51.41 million−1540.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy